IDEXX Laboratories, Inc. (NASDAQ:IDXX) Holdings Decreased by RFG Advisory LLC

RFG Advisory LLC trimmed its position in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 3.7% in the second quarter, Holdings Channel.com reports. The fund owned 1,186 shares of the company’s stock after selling 46 shares during the period. RFG Advisory LLC’s holdings in IDEXX Laboratories were worth $578,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also made changes to their positions in the company. Vanguard Group Inc. grew its stake in IDEXX Laboratories by 1.2% during the 1st quarter. Vanguard Group Inc. now owns 8,476,054 shares of the company’s stock worth $4,576,476,000 after buying an additional 98,387 shares during the last quarter. Franklin Resources Inc. grew its stake in IDEXX Laboratories by 2.1% during the 4th quarter. Franklin Resources Inc. now owns 1,405,824 shares of the company’s stock worth $780,303,000 after buying an additional 28,475 shares during the last quarter. Capital World Investors grew its stake in IDEXX Laboratories by 1.1% during the 4th quarter. Capital World Investors now owns 1,022,678 shares of the company’s stock worth $567,648,000 after buying an additional 11,351 shares during the last quarter. Norges Bank bought a new position in IDEXX Laboratories during the 4th quarter worth $512,190,000. Finally, Charles Schwab Investment Management Inc. grew its stake in IDEXX Laboratories by 3.1% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 476,799 shares of the company’s stock worth $264,647,000 after buying an additional 14,264 shares during the last quarter. 87.84% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on IDXX shares. Morgan Stanley reduced their price target on IDEXX Laboratories from $620.00 to $596.00 and set an “overweight” rating for the company in a research report on Tuesday, May 14th. Stifel Nicolaus reduced their price target on IDEXX Laboratories from $520.00 to $510.00 and set a “hold” rating for the company in a research report on Monday, June 24th. Barclays reduced their price target on IDEXX Laboratories from $655.00 to $570.00 and set an “overweight” rating for the company in a research report on Thursday, May 2nd. StockNews.com lowered IDEXX Laboratories from a “buy” rating to a “hold” rating in a research report on Wednesday, July 10th. Finally, BTIG Research initiated coverage on IDEXX Laboratories in a research report on Thursday, July 25th. They set a “buy” rating and a $580.00 price target for the company. Three equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $582.88.

Insider Activity

In other news, Director Bruce L. Claflin sold 200 shares of the company’s stock in a transaction on Friday, May 17th. The stock was sold at an average price of $540.80, for a total transaction of $108,160.00. Following the completion of the sale, the director now directly owns 161 shares of the company’s stock, valued at $87,068.80. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. 2.11% of the stock is currently owned by company insiders.

IDEXX Laboratories Price Performance

Shares of IDEXX Laboratories stock traded down $2.91 during trading on Monday, hitting $479.93. The stock had a trading volume of 325,871 shares, compared to its average volume of 490,578. IDEXX Laboratories, Inc. has a fifty-two week low of $372.50 and a fifty-two week high of $583.39. The firm has a market cap of $39.64 billion, a P/E ratio of 46.74, a PEG ratio of 3.91 and a beta of 1.32. The company has a debt-to-equity ratio of 0.40, a current ratio of 1.57 and a quick ratio of 1.16. The business has a fifty day moving average of $485.85 and a two-hundred day moving average of $512.89.

IDEXX Laboratories (NASDAQ:IDXX) last announced its earnings results on Tuesday, August 6th. The company reported $2.44 EPS for the quarter, missing the consensus estimate of $2.88 by ($0.44). IDEXX Laboratories had a net margin of 23.26% and a return on equity of 63.66%. The company had revenue of $1 billion for the quarter, compared to analysts’ expectations of $1.01 billion. During the same period in the prior year, the company earned $2.67 earnings per share. The company’s revenue for the quarter was up 6.4% on a year-over-year basis. On average, sell-side analysts expect that IDEXX Laboratories, Inc. will post 11 earnings per share for the current fiscal year.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.